Trial Profile

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary) ; Tucatinib (Primary) ; Fulvestrant
Indications Advanced breast cancer; Biliary cancer; Brain cancer; Cervical cancer; HER2 negative breast cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer; Uterine cancer
Focus Therapeutic Use
Sponsors Seagen

Most Recent Events

19 Jun 2025 Planned End Date changed from 30 Apr 2025 to 30 Apr 2026.
30 Apr 2025 Planned End Date changed from 31 May 2025 to 30 Apr 2025.
01 Mar 2025 Results (n=31 heavily pretreated female patients with HER2-mutated metastatic breast cancer who were also HER2 negative per local testing) published in the Nature Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com